As biological data volume continues to grow, sequence-based AI is poised to become the dominant discovery layer across pharma ...

Ellipses and Innolake will collaborate closely on the development of ILB-3101/EP0028, which is currently in a Phase 1 trial in China sponsored by Innolake. Ellipses will initiate a Phase 1 clinical ...

BioAtla Inc. company and executive profile by Barron's. View the latest BCAB company infomation and executive bios.

GSK is staking billions on a new way to protect people from life‑threatening food allergies, agreeing to buy RAPT ...

Artificial intelligence (AI) and “protein language” models can speed the design of monoclonal antibodies that prevent or reduce the severity of potentially life-threatening viral infections, according ...

Learn how pH-sensitive dye detection supports reliable ADC internalization assays and insight into cellular uptake mechanisms ...

Researchers at Colorado State University have determined how to use artificial intelligence to modify antibodies so they act ...

Researchers have developed a new class of antibodies that amplify the immune system’s ability to fight cancer. By clustering ...

~ Designation enables an enhanced development path for VTx-002 and underscores its disease-modifying potential in ALS, a universally fatal disease with no cure ~ Milestone follows recent IND clearance ...

SAN FRANCISCO and BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for ...

JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid ...